

Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score

Piers Klein,^a Liqi Shu,^b Thanh N. Nguyen,^a James E. Siegler,^c Setareh Salehi Omran,^d Alexis N. Simpkins,^e Mirjam Heldner,^f Adam de Havenon,^g Hugo J. Aparicio,^a Mohamad Abdalkader,^a Marios Psychogios,^h Maria Cristina Vedovati,ⁱ Maurizio Paciaroni,^j Rascha von Martial,^f David S. Liebeskind,^k Diana Aguiar de Sousa,^l Jonathan M. Coutinho,^m Shadi Yaghi,^b for the ACTION-CVT Study Group

^aDepartment of Neurology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA

^bDepartment of Neurology, Brown University, Providence, RI, USA

^cDepartment of Neurology, Cooper Neurological Institute, Cooper University Hospital, Camden, NJ, USA

^dDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA

^eDepartment of Neurology, University of Florida, Gainesville, FL, USA

^fDepartment of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland

^gDepartment of Neurology, Yale University, New Haven, CT, USA

^hDepartment of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland

ⁱDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy

^jNeurology-Stroke Unit, IRCCS MultiMedica, Milano, Italy

^kDepartment of Neurology, University of California at Los Angeles, Los Angeles, CA, USA

^lDepartment of Neurosciences and Mental Health, Neurology Service, Hospital de Santa Maria/CHULN, University of Lisbon, Lisbon, Portugal

^mDepartment of Neurology, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands

Background We identified risk factors, derived and validated a prognostic score for poor neurological outcome and death for use in cerebral venous thrombosis (CVT).

Methods We performed an international multicenter retrospective study including consecutive patients with CVT from January 2015 to December 2020. Demographic, clinical, and radiographic characteristics were collected. Univariable and multivariable logistic regressions were conducted to determine risk factors for poor outcome, mRS 3–6. A prognostic score was derived and validated.

Results A total of 1,025 patients were analyzed with median 375 days (interquartile range [IQR], 180 to 747) of follow-up. The median age was 44 (IQR, 32 to 58) and 62.7% were female. Multivariable analysis revealed the following factors were associated with poor outcome at 90-day follow-up: active cancer (odds ratio [OR], 11.20; 95% confidence interval [CI], 4.62 to 27.14; $P < 0.001$), age (OR, 1.02 per year; 95% CI, 1.00 to 1.04; $P = 0.039$), Black race (OR, 2.17; 95% CI, 1.10 to 4.27; $P = 0.025$), encephalopathy or coma on presentation (OR, 2.71; 95% CI, 1.39 to 5.30; $P = 0.004$), decreased hemoglobin (OR, 1.16 per g/dL; 95% CI, 1.03 to 1.31; $P = 0.014$), higher NIHSS on presentation (OR, 1.07 per point; 95% CI, 1.02 to 1.11; $P = 0.002$), and substance use (OR, 2.34; 95% CI, 1.16 to 4.71; $P = 0.017$). The derived IN-REvASC score outperformed ISCVT-RS for the prediction of poor outcome at 90-day follow-up (area under the curve [AUC], 0.84 [95% CI, 0.79 to 0.87] vs. AUC, 0.71 [95% CI, 0.66 to 0.76], $\chi^2 P < 0.001$) and mortality (AUC, 0.84 [95% CI, 0.78 to 0.90] vs. AUC, 0.72 [95% CI, 0.66 to 0.79], $\chi^2 P = 0.03$).

Conclusions Seven factors were associated with poor neurological outcome following CVT. The IN-REvASC score increased prognostic accuracy compared to ISCVT-RS. Determining patients at highest risk of poor outcome in CVT could help in clinical decision making and identify patients for targeted therapy in future clinical trials.

Keywords Stroke; Sinus thrombosis, intracranial; Prognosis

Correspondence: Shadi Yaghi
Department of Neurology, Warren Alpert
Medical School of Brown University, 593
Eddy Street APC 5, Providence, RI 02903,
USA
Tel: +1-401-444-8806
Fax: +1-401-444-8781
E-mail: shadiyaghi@yahoo.com
<https://orcid.org/0000-0003-0031-1004>

Received: May 17, 2022

Revised: July 29, 2022

Accepted: August 11, 2022

Introduction

Cerebral venous thrombosis (CVT) is a rare cause of stroke, with an estimated incidence of approximately 1.5 per 100,000 person-years.^{1,2} The condition is more common in young patients, especially young women. CVT involves thrombus formation in the venous system of the brain including the deep veins, superficial veins, and sinuses. Occlusions may result in venous infarct, intracranial hemorrhage, and cerebral edema. Overall mortality is low with a case fatality rate of 5% to 10%.³⁻⁵ In accordance with its rarity, CVT is less well understood than other major causes of stroke.

Prior studies of CVT have identified a number of factors associated with poor neurological outcome or disability including coma, cerebral edema, focal deficit, and thrombosis of the deep cerebral vessels.^{3,5-9} However, many of these studies have been small and limited in the variables under study. To date, the most influential study of CVT patients is the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) published in 2004.⁵ From this cohort, the ISCVT risk score (IS-CVT-RS) for poor neurological outcome was derived and validated, and has subsequently seen more widespread use than similar scores.¹⁰⁻¹⁴ Since the publication of ISCVT, there have been advances in the diagnosis and treatment of CVT patients.¹⁵⁻¹⁸ However, it remains unclear whether these advances have impacted outcomes of CVT patients. Risk stratification of patients may help with clinical decision making and identify those who could benefit from further treatment and study.

In this large observational study, we sought to identify clinical, laboratory, and imaging factors associated with poor neurological outcome, modified Rankin Scale (mRS) 3–6, and to derive and validate a prognostic score for poor neurological outcome at 90 days following a diagnosis of CVT.

Methods

Institutional Review Board approval was obtained from each participating center to conduct the study. Written informed consent by the patients was waived due to the retrospective nature of this study. De-identified data are available upon reasonable request to the corresponding author. This study followed the TRIPOD reporting guidelines (Supplementary Table 1).

Patient population

The Anticoagulation in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT) study was a large multicenter international retrospective cohort study that enrolled consecutive patients with a confirmed diagnosis of CVT from January 2015

through December 2020.^{17,19,20} Patients were included from 27 centers in the United States, Europe, and New Zealand. Participating centers were tertiary care academic medical centers spanning multiple national models of care delivery.

Outcomes

A single primary outcome and a single secondary outcome were defined *a priori*. The primary outcome was presence of poor neurological outcome, defined as mRS 3–6, at 90-day follow-up. The secondary outcome was all-cause mortality.

Inclusion criteria

A total of 1,025 patients were enrolled in ACTION-CVT. Potential patients were identified using previously validated International Classification of Diseases, ninth revision (ICD-9; 325.0, 437.6, and 671.5) and ICD-10 codes (I67.6) with appropriate sensitivity and specificity for CVT.^{21,22} The diagnosis of CVT was confirmed by review of the patient's medical record and imaging studies by participating sites. Inclusion for each analysis was based on the presence of the required outcome variables at the specified time point.

Collected variables

Demographic factors, in-hospital treatments, follow-up variables, clinical, imaging, and laboratory factors were collected. All variables were collected via manual chart abstraction by investigators at participating sites. Standardized variable definitions were used. Substance use was defined as active smoking or non-medical use of drugs other than alcohol and tobacco. Hypercoagulable factors were defined as one or more antiphospholipid antibodies, protein C <65, protein S <70, antithrombin <80, factor V Leiden mutation, or prothrombin gene mutation. Collected variables are further described in a previous publication.¹⁷

Statistical analysis

To ensure data integrity and consistency, data verification was conducted with queries sent to participating sites. Death was carried forward to future timepoints. Missing data were not imputed. Patients were included in the analysis for each outcome if the required outcome variables were available at the specified time point.

Factors included in the univariable analysis were selected based on previously shown associations with CVT outcomes or based on biological plausibility. Factors with low prognostic value (e.g., tracheostomy during hospitalization), a lack of biological plausibility (e.g., coronavirus disease 2019 [COVID-19] testing), or reflective of clinician treatment decisions (e.g., neu-

rosurgical treatment), were not included. Demographic variables were also included in the univariable analysis due to previously identified disparities in CVT and other forms of stroke.^{5,23} Univariable analysis of focal deficit was performed in patients without global deficit (i.e., encephalopathy and coma). Collinear factors were dichotomized, discarded, or combined as appropriate. Odds ratios (ORs) for continuous variables were calculated as ratio per unit.

For both univariable and multivariable analyses, outcomes were dichotomized based upon mRS score at the specified time point for each outcome. Between-group univariable comparisons were done by two-sided t-test, chi-square test, Fisher's exact test, or rank sum test as appropriate. The univariable analysis was carried out only based on the primary outcome. Factors found to be associated in univariable analysis were fed into the multivariable analysis. Statistical significance for all analyses was set at $\alpha=0.05$.

A risk scoring model was generated based upon the results of the multivariable analysis. A nomogram was generated based on the multivariable regression result of all potential prognostic factors ($P<0.20$) from the multivariable analysis. This variable filtering step increases the number of events per predictor variable, reducing the likelihood of model overfitting. The National Institutes of Health Stroke Scale (NIHSS) was divided into five discrete categories. The Liu method for cut-point estimation²⁴ was used for dichotomization: age was di-

chotomized at 50 years, creatinine was dichotomized at >1.0 mg/dL, and hemoglobin was dichotomized at ≥ 12.0 g/dL. Nomogram generated point values were rounded to the nearest integer to create the IN-REvASC score model containing nine factors: intracranial hemorrhage, NIHSS, Black race, encephalopathy or coma on presentation, age, anemia, substance use, creatinine, and active cancer (Figure 1). The previously described ISCVT-RS model score was calculated.¹⁰ The prognostic value of both models was tested using a receiver operating characteristic curve under non-parametric assumptions. The area under the curve (AUC) was used to determine prognostic accuracy. Internal validation of models was performed using





Figure 2. Study flow chart. ACTION-CVT, Anticoagulation in the Treatment of Cerebral Venous Thrombosis; mRS, modified Rankin Scale.

IN-REvASC		Score
Intracranial hemorrhage on admission	No	0
	Yes	1
NIHSS	0	0
	1–10	2
	11–20	4
	21–30	6
	>30	8
Black Race	No	0
	Yes	3
Encephalopathy or coma on presentation	No	0
	Yes	4
Age >50	No	0
	Yes	3
Anemia (hemoglobin <12.0 g/dL)	No	0
	Yes	2
Substance use	No	0
	Yes	4
Active Cancer	No	0
	Yes	10
Creatinine >1.0	No	0
	Yes	2
Total		35

Figure 1. Prognostic models for poor outcome at 90-day follow-up. AUC, area under the curve; ISCVT-RS, International Study on Cerebral Vein and Dural Sinus Thrombosis risk score.



the bootstrap method with 100 iterations. Models were compared using the chi-square test. All data analyses were carried out using Stata version 15.1 (StataCorp., College Station, TX, USA).

Results

Data were collected on 1,025 patients with CVT from 27 sites in the United States, Europe, and New Zealand. Baseline characteristics of the cohort are summarized in Table 1. The median age of included subjects was 44 years (interquartile range [IQR], 32 to 58), 62.7% (640) were women, and 15.7% (160) were Black. The median length of follow-up was 375 days (IQR, 180 to 747). Endovascular therapy was performed in 8.7% (89) of patients and 87.8% (900) patients were treated with oral anticoagulation.¹⁷ There were 649 patients included in the primary analysis and 101 had poor outcome (Figure 2). In the univariable analysis, 11 factors were associated with poor outcome at 90 days and two factors were inversely associated with poor outcome at 90 days. These 13 factors were fed into the multivariable analyses (Table 2).

Poor outcome at 90-day follow-up

At 90-day follow-up, 15.6% (101/649) of patients had poor

outcome, mRS 3–6. Active cancer (OR, 11.20; 95% confidence interval [CI], 4.62 to 27.14; $P<0.001$), age (OR, 1.02 per year; 95% CI, 1.00 to 1.04; $P=0.039$), Black race (OR, 2.17; 95% CI, 1.10 to 4.27; $P=0.025$), encephalopathy or coma on presentation (OR, 2.71; 95% CI, 1.39 to 5.30; $P=0.004$), decreased hemoglobin (OR, 1.16 per g/dL; 95% CI, 1.03 to 1.31; $P=0.014$), higher NIHSS on presentation (OR, 1.07 per point; 95% CI, 1.02 to 1.11; $P=0.002$), and substance use (OR, 2.34; 95% CI, 1.16 to 4.71; $P=0.017$) were associated with poor outcome at 90 days follow-up (Table 3). Among patients with zero prognostic factors, 2.9% (7/239) had poor outcome at 90 days. Poor outcome at 90 days was present in 12.9% (31/240), 26.1% (29/111), and 57.6% (28/59) of patients with 1, 2, or 3+ prognostic factors, respectively.

Mortality

Mortality in the cohort was 6.6% (43/649) at 90-day follow-up and the in-hospital mortality was 3.9% (25/649) during this time period. Mortality was 6.8% (70/1,025) at last follow-up (median 375 days [IQR, 180 to 747]). The incidence rate for mortality was 5.13 per 100 person-years with a median follow-up of 375 days. Active cancer (OR, 12.17; 95% CI, 5.45 to 27.16; $P<0.001$), Black race (OR, 2.62; 95% CI, 1.20 to 5.69; $P=0.015$), and substance use (OR, 2.17; 95% CI, 1.03 to 4.60;

Table 1. Demographic and baseline clinical characteristics of the ACTION-CVT study population

Factor	No./total no. (%)	Median (IQR)
Age (yr)		44 (32–58)
Race		
White	710/1,018 (69.7)	
Black	160/1,018 (15.7)	
Asian	40/1,018 (3.9)	
Other	108/1,018 (10.6)	
Ethnicity		
Hispanic	102/1,014 (10.1)	
Sex		
Female	643/1,025 (62.7)	
BMI (kg/m ²)		28.00 (23.88–33.10)
Medical history		
Chronic kidney disease	39/1,023 (3.8)	
Active cancer	67/1,023 (6.5)	
Prior DVT	101/1,024 (9.9)	
Prior PE	57/1,023 (5.6)	
Antiphospholipid syndrome	11/1,001 (1.1)	
COVID-19 tested	148/1,025 (14.4)	
COVID-19 positive	8/148 (5.4)	
12 Weeks postpartum	38/1,016 (3.7)	

Table 1. Continued

Factor	No./total no. (%)	Median (IQR)
Recent mastoiditis or sinusitis	89/1,025 (8.7)	
Recent lumbar puncture	46/1,025 (4.5)	
Recent head trauma	89/1,024 (8.7)	
Smoking	146/1,019 (14.3)	
Alcohol abuse	84/1,019 (8.2)	
Substance use	59/1,019 (5.8)	
Family history of VTE	101/1,018 (9.9)	
Medications		
Antiplatelet	104/1,024 (10.2)	
Warfarin	39/1,025 (3.8)	
DOAC	32/1,025 (3.1)	
Birth control	235/1,007 (23.3)	
Days from symptoms to diagnosis		4 (1–10)
Previously discharged from ED with missed diagnosis	157/1,024 (15.3)	
Symptoms		
Headache	762/1,023 (74.5)	
Focal deficit	401/1,024 (39.2)	
Seizure	243/1,024 (23.7)	
Encephalopathy	209/1,024 (20.4)	
Coma	29/1,024 (2.8)	
Papilledema	100/958 (10.4)	
NIHSS		0.00 (0.00–3.00)
Imaging features		
Venous infarct	273/1,025 (26.6)	
Edema	318/1,025 (31.0)	
Any hemorrhage	390/1,025 (38.0)	
CVT location		
Superficial veins	745/1,023 (72.8)	
Deep veins	118/1,023 (11.5)	
Cortical vein only	30/1,023 (2.9)	
Both superficial and deep veins	130/1,023 (12.7)	
Laboratory features		
1+ Antiphospholipid antibody positive	82/839 (9.8)	
Protein C <65	60/571 (10.5)	
Protein S <70	120/559 (21.5)	
Antithrombin <80	82/572 (14.3)	
Factor V mutation	47/679 (6.9)	
Prothrombin mutation	32/635 (5.0)	
White blood count (10 ³ /mL)		9.60 (7.40–12.50)
Hemoglobin (g/dL)		13.30 (11.70–14.70)
Platelet count (10 ³ /mL)		247.00 (200.00–309.00)
Creatinine (mg/dL)		0.80 (0.69–0.95)

ACTION-CVT, Anticoagulation in the Treatment of Cerebral Venous Thrombosis; IQR, interquartile range; BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; COVID-19, coronavirus disease 2019; VTE, venous thromboembolism; DOAC, direct oral anticoagulation; ED, emergency department; NIHSS, National Institutes of Health Stroke Scale; CVT, cerebral venous thrombosis.

Table 2. Univariable prognostic factors of poor neurological outcome at 90-day follow-up

Factor	mRS 0–2	mRS 3–6	OR	95% CI	P
Age (yr)	43.95±16.0	51.95±16.79	1.03	1.02–1.04	<0.001
Race					
White	393/546 (72.0)	54/99 (54.5)	0.47	0.30–0.72	0.001
Black	83/546 (15.2)	29/99 (29.3)	2.31	1.41–3.78	0.001
Asian	21/546 (3.8)	2/99 (2.0)	0.52	0.12–2.23	0.557
Other	49/546 (9.0)	14/99 (14.1)	1.67	0.88–3.16	0.111
Ethnicity					
Hispanic	61/547 (11.2)	6/98 (6.1)	0.52	0.22–1.24	0.133
Sex					
Female	352/548 (64.2)	58/101 (57.4)	0.75	0.49–1.16	0.192
Medical history					
Active cancer	15/548 (2.7)	23/100 (23.0)	10.61	5.31–21.22	<0.001
Prior VTE	58/548 (10.6)	18/101 (17.8)	1.83	1.03–3.27	0.038
Antiphospholipid syndrome	7/548 (1.3)	2/97 (2.1)	1.63	0.33–7.95	0.631
COVID-19 positive	2/72 (2.8)	2/20 (10.0)	3.89	0.51–29.53	0.205
12 Weeks postpartum	20/539 (3.7)	2/101 (2.0)	0.52	0.12–2.28	0.555
Recent mastoiditis or sinusitis	47/548 (8.6)	10/101 (9.9)	1.17	0.57–2.40	0.666
Recent lumbar puncture	24/548 (4.4)	6/101 (5.9)	1.38	0.55–3.46	0.492
Recent head trauma	52/548 (9.5)	15/101 (14.9)	1.66	0.90–3.09	0.104
Substance use	77/542 (14.2)	25/100 (25.0)	2.01	1.21–3.36	0.007
Family history of VTE	66/543 (12.2)	6/100 (6.0)	0.46	0.19–1.10	0.073
Medications					
Warfarin	14/548 (2.6)	3/101 (3.0)	1.17	0.33–4.14	0.737
DOAC	14/548 (2.6)	4/101 (4.0)	1.57	0.51–4.88	0.504
Birth control	138/534 (25.8)	12/101 (11.9)	0.39	0.21–0.73	0.002
Days from symptoms to diagnosis	4 (1–10)	3 (0–8)	1.00	0.99–1.01	0.055
Previously discharged from ED with missed diagnosis	85/548 (15.5)	13/101 (12.9)	0.81	0.43–1.51	0.496
Symptoms					
Focal deficit	147/450 (32.7)	14/43 (32.6)	1.00	0.51–1.94	0.988
Seizure	135/548 (24.6)	28/101 (27.7)	1.17	0.73–1.89	0.511
Encephalopathy or coma	98/548 (17.9)	58/101 (57.4)	6.19	3.95–9.72	<0.001
NIHSS	0 (0–2)	3.5 (1–12)	1.11	1.07–1.14	<0.001
Imaging features					
Venous infarct	145/548 (26.5)	28/101 (27.7)	1.07	0.66–1.72	0.792
Edema	161/548 (29.4)	46/101 (45.5)	2.01	1.30–3.10	0.001
Any hemorrhage	207/548 (37.8)	52/101 (51.5)	1.75	1.14–2.68	0.010
CVT location					
Superficial veins	385/547 (70.4)	73/101 (72.3)	1.10	0.68–1.76	0.701
Deep veins	71/547 (13.0)	12/101 (11.9)	0.90	0.47–1.74	0.761
Cortical vein only	14/547 (2.6)	2/101 (2.0)	0.77	0.17–3.44	1.000
Both superficial and deep veins	77/547 (14.1)	14/101 (13.9)	0.98	0.53–1.81	0.954
Laboratory features					
1+ Hypercoagulable factor	198/548 (36.1)	22/101 (21.8)	0.49	0.30–0.82	0.005
White blood count (10 ³ /mL)	10.04±3.97	10.77±4.66	1.04	0.99–1.10	0.103
Hemoglobin (g/dL)	13.06±2.35	12.08±2.52	0.85	0.78–0.93	<0.001
Platelet count (10 ³ /mL)	269.12±102.14	255.45±117.82	1.00	1.00–1.00	0.234
PTT (sec)	30.41±21.07	28.65±9.92	0.99	0.98–1.01	0.430
Creatinine (mg/dL)	0.84±0.26	0.9±0.37	1.95	1.00–3.81	0.048

Values are presented as mean±standard deviation or number/total number (%).

mRS, modified Rankin Scale; OR, odds ratio; CI, confidence interval; VTE, venous thromboembolism; COVID-19, coronavirus disease 2019; DOAC, direct oral anticoagulation; ED, emergency department; NIHSS, National Institutes of Health Stroke Scale; CVT, cerebral venous thrombosis; PTT, partial thromboplastin time.

$P=0.042$) were associated with mortality (Table 3).

IN-REvASC score

The IN-REvASC score used nine factors simplified from a no-mogram regression: Intracranial hemorrhage, NIHSS, Black Race, Encephalopathy or coma at admission, Age, Anemia, Substance use, Creatinine, and active Cancer. Intracranial hemorrhage was assigned one point. Anemia, defined as hemoglobin less than 12.0 mg/dL, and creatinine greater than 1.0 mg/dL were assigned two points. Black race and age greater than 50 were assigned three points. Encephalopathy or coma on presentation and substance use were assigned four points. NIHSS of 1–10 was assigned two points, 11–20 was assigned four points, 21–30 was assigned six points, and greater than 30 was

assigned eight points. Active cancer was assigned 10 points (Figure 1).

The IN-REvASC (AUC, 0.84; 95% CI, 0.78 to 0.89) score outperformed ISCVT-RS (AUC, 0.71; 95% CI, 0.66 to 0.77; $\chi^2 P<0.001$) for the prediction of poor outcome at 90-day follow-up. The probability of poor outcome in those with a low risk, IN-REvASC <10 , was 5.1% (23/447) (Figure 1). For those with a moderate risk, IN-REvASC ≥ 10 to <20 , the probability was 38.8% (40/103). For those with a high risk, IN-REvASC ≥ 20 , the probability was 90.0% (9/10) (Figure 3).

The IN-REvASC score (AUC, 0.84; 95% CI, 0.78 to 0.90) outperformed ISCVT-RS (AUC, 0.72; 95% CI, 0.66 to 0.79; $\chi^2 P=0.03$) for the prediction of mortality. For those in the low (IN-REvASC <10), moderate (IN-REvASC ≥ 10 to <20), and high

Table 3. Multivariable prognostic factors of poor outcome at 90-day follow-up and mortality

Factor	Poor outcome			Mortality		
	OR	95% CI	P	OR	95% CI	P
Active cancer	11.20	4.62–27.14	<0.001	12.17	5.45–27.16	<0.001
Age	1.02	1.00–1.04	0.039	1.02	1.00–1.04	0.083
Birth control	1.17	0.52–2.65	0.700	0.32	0.07–1.47	0.143
Black race	2.17	1.10–4.27	0.025	2.62	1.20–5.69	0.015
Creatinine	1.97	0.72–5.33	0.185	1.40	0.68–2.86	0.361
Encephalopathy or coma	2.71	1.39–5.30	0.004	1.72	0.79–3.76	0.170
Hemoglobin	0.86	0.77–0.97	0.014	0.97	0.85–1.10	0.618
1+ Hypercoagulable factor	0.88	0.46–1.69	0.694	0.93	0.40–2.14	0.857
Cerebral edema on imaging	0.89	0.46–1.72	0.726	0.90	0.41–1.96	0.789
Hemorrhage on imaging	1.62	0.85–3.09	0.145	1.73	0.79–3.78	0.171
NIHSS	1.07	1.02–1.11	0.002	1.02	0.98–1.07	0.338
Prior VTE	1.64	0.71–3.77	0.246	0.91	0.35–2.36	0.845
Substance use	2.34	1.16–4.71	0.017	2.17	1.03–4.60	0.042

OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; VTE, venous thromboembolism.




Figure 3. Distribution of scores on the modified Rankin Scale (mRS) at 90 days according to IN-REvASC risk groups.

(IN-REvASC ≥ 20) risk categories, the mortality risks were 1.9% (12/642), 15.3% (24/157), and 37.5% (6/16), respectively.

Losses to follow-up

Of the total study population, 16.3% (167/1025) were lost to follow-up prior to 90 days. Those lost to follow-up were less likely to be female, more likely to have substance use, and had higher median NIHSS on presentation compared to those with 90-day or greater follow-up. However, there were no differences in rates of in-hospital interventions (intubation, neurosurgical treatment, percutaneous endoscopic gastrostomy placement, tracheostomy) suggesting a similar clinical course as those with follow-up (Table 4).

Discussion

In this large, multicenter, international cohort study, we found that in patients with CVT, active cancer, age, Black race, encephalopathy or coma on presentation, decreased hemoglobin, higher NIHSS on presentation, and substance use were associ-

ated with poor outcome, defined as mRS 3–6, at 90 days. In contrast to prior reports, sex, clot location, and birth control^{3,5} use were not associated with poor outcomes in this study.

Two prognostic score models were tested in our cohort: IN-REvASC and ISCVT-RS. In line with previous publications, ISCVT-RS achieved an AUC of 0.71 for poor 90-day outcome and 0.72 for mortality when tested in our cohort. However, three of the six scoring factors used in ISCVT-RS, male gender, parenchymal hemorrhage, and deep thrombus location, were not associated with poor outcome in our study. Compared to ISCVT-RS, the IN-REvASC score offers increased ease of use and improvement in prognostic accuracy with an AUC of 0.84 for poor 90-day outcome and 0.84 for mortality. The IN-REvASC score uses a series of factors associated with poor outcome and readily available clinical data in usual clinical practice increasing the ease of use. The nomogram scoring method used to generate IN-REvASC allows for the evaluation of a complex regression without any calculation required. IN-REvASC score cutoffs stratify patients into low, moderate, and high-risk groups for both poor outcome at 90-day follow-up

Table 4. Comparison of patients with and without 90-day follow-up

Factor	<90-day follow-up	≥ 90 -day follow-up	<i>P</i>
Age (yr)	47.19 \pm 17.77	45.19 \pm 16.64	0.163
Race			
White	109/165 (66.1)	577/812 (71.1)	0.201
Black	23/165 (13.9)	126/812 (15.5)	0.607
Asian	10/165 (6.1)	29/812 (3.6)	0.136
Other	23/165 (13.9)	80/812 (9.9)	0.119
Ethnicity			
Hispanic	19/162 (11.7)	83/811 (10.2)	0.571
Sex			
Female	94/167 (56.3)	531/817 (65.0)	0.033
BMI (kg/m ²)	28.17 \pm 6.76	29.64 \pm 7.72	0.024
Medical history			
Chronic kidney disease	11/167 (6.6)	25/815 (3.1)	0.027
Active cancer	13/167 (7.8)	38/815 (4.7)	0.098
Prior VTE	18/167 (10.8)	96/817 (11.8)	0.721
Antiphospholipid syndrome	1/158 (0.6)	10/805 (1.2)	1.000
COVID-19 tested	40/167 (24.0)	98/817 (12.0)	0.000
COVID-19 positive	2/40 (5.0)	4/98 (4.1)	1.000
12 Weeks postpartum	8/165 (4.8)	28/810 (3.5)	0.388
Recent mastoiditis or sinusitis	19/167 (11.4)	68/817 (8.3)	0.205
Recent lumbar puncture	10/167 (6.0)	34/817 (4.2)	0.298
Recent head trauma	16/167 (9.6)	67/816 (8.2)	0.562
Smoking	35/167 (21.0)	102/811 (12.6)	0.004

Table 4. Continued

Factor	<90-day follow-up	≥90-day follow-up	P
Alcohol abuse	21/167 (12.6)	58/811 (7.2)	0.019
Substance use	40/167 (24.0)	120/810 (14.8)	0.016
Family history of VTE	13/167 (7.8)	87/810 (10.7)	0.251
Medications			
Antiplatelet	13/167 (7.8)	85/816 (10.4)	0.301
Warfarin	10/167 (6.0)	28/817 (3.4)	0.118
DOAC	5/167 (3.0)	25/817 (3.1)	1.000
Birth control	40/163 (24.5)	192/803 (23.9)	0.864
Days from symptoms to diagnosis	3.0 (1.0–7.0)	4.0 (1.0–10.0)	0.029
Previously discharged from ED with missed diagnosis	27/167 (16.2)	126/816 (15.4)	0.813
Symptoms			
Focal deficit	42/127 (33.1)	230/657 (35.0)	0.675
Seizure	39/167 (23.4)	198/816 (24.3)	0.802
Encephalopathy or coma	40/167 (24.0)	159/816 (19.5)	0.191
Papilledema	7/154 (4.5)	88/766 (11.5)	0.010
NIHSS	1.0 (0.0–4.0)	0.0 (0.0–2.0)	0.004
Imaging features			
Venous infarct	47/167 (28.1)	214/817 (26.2)	0.603
Edema	54/167 (32.3)	247/817 (30.2)	0.591
Any hemorrhage	62/167 (37.1)	309/817 (37.8)	0.866
CVT location			
Superficial veins	125/167 (74.9)	587/815 (72.0)	0.456
Deep veins	19/167 (11.4)	93/815 (11.4)	0.990
Cortical vein only	5/167 (3.0)	25/815 (3.1)	1.000
Both superficial and deep veins	18/167 (10.8)	110/815 (13.5)	0.342
Laboratory features			
1+ Antiphospholipid antibody positive	8/123 (6.5)	72/690 (10.4)	0.178
Protein C <65	10/67 (14.9)	48/492 (9.8)	0.193
Protein S <70	15/64 (23.4)	103/484 (21.3)	0.693
Antithrombin <80	11/66 (16.7)	69/498 (13.9)	0.538
Factor V mutation	5/94 (5.3)	42/571 (7.4)	0.663
Prothrombin mutation	2/87 (2.3)	30/535 (5.6)	0.294
1+ Hypercoagulable factor	37/167 (22.2)	277/817 (33.9)	0.003
White blood count (10 ³ /mL)	10.72±4.12	10.05±4.12	0.059
Hemoglobin (g/dL)	13.07±2.38	13.02±2.42	0.842
Platelet count (10 ³ /mL)	259.88±95.19	266.32±103.66	0.463
Creatinine (mg/dL)	0.94±0.81	0.85±0.33	0.025
Hospital course			
Intubation	20/167 (12.0)	90/816 (11.0)	0.724
Tracheostomy	2/167 (1.2)	21/817 (2.6)	0.403
PEG tube insertion	6/167 (3.6)	25/817 (3.1)	0.719
Neurosurgical treatment	6/167 (3.6)	45/817 (5.5)	0.309

Values are presented as mean±standard deviation, number/total number (%), or median (interquartile range).

BMI, body mass index; DVT, deep vein thrombosis; COVID-19, coronavirus disease 2019; DOAC, direct oral anticoagulation; ED, emergency department; NIHSS, National Institutes of Health Stroke Scale; CVT, cerebral venous thrombosis; PEG, percutaneous endoscopic gastrostomy.

and mortality. For those in the low-risk group, the probability of poor outcome was 5.1% (23/447) and the probability of mortality was 1.9% (12/642). For the moderate-risk group, these probabilities were 38.8% (40/103) and 15.3% (24/157). For the high-risk group, these probabilities were 90.0% (9/10) and 37.5% (6/16).

Prior studies have demonstrated that the presence of neurological symptoms is associated with worse outcome following CVT.^{3,5,7,25,26} This study more specifically characterizes the association, demonstrating that increasing severity of neurological symptoms, as measured by NIHSS, is associated with higher odds of poor neurological outcome at 90 days. Encephalopathy or coma on presentation were also associated with poor 90-day outcome suggesting that both the overall severity of neurological symptoms as well as their localization are important.

In this study, we noted that Black race was associated with poor outcomes following CVT. Specifically, Black race was associated with an increased rate of poor neurologic outcome at 90 days (OR, 2.17) and increased mortality (OR, 2.62). In prior ischemic stroke literature, Black race was also associated with poor outcomes indicating that this racial disparity in outcomes is present across multiple forms of stroke.²³ Additionally, the incidence of CVT has been observed to be significantly higher in Black populations.²⁷ Taken together, Black patients are disproportionately more likely to experience CVT and more likely to experience poor outcomes. This disparity is likely the result of differences in social determinants of health, inequities in healthcare access, and experiences of structural racism between racial groups.²⁸⁻³² Importantly, the inclusion of race as a factor in the IN-REvASC score is an acknowledgement of an observed disparity only, not a statement of an intrinsic biological difference in CVT between racial groups. Caution should be taken when using these results to inform the care of individual patients and when enrolling patients in future studies. Future research is essential to identify and address the factors leading to these disparities.

Active cancer was associated with poor outcome at 90-day follow-up and mortality, and was the strongest prognostic factor for both outcomes, in agreement with previous literature.^{5,6} Anemia has been previously identified as a risk factor for poor outcome following both ischemic stroke³³ and CVT³⁴ and, in our study, decreased hemoglobin was associated with poor outcome at 90-day follow-up. Serum creatinine greater than 1.0 mg/dL was also associated with poor outcome implicating poor renal function or hydration status in recovery after CVT, the latter of which has been previously suggested as a driver of poor outcome in CVT patients.³⁵

Evidence for the role of sex in CVT outcomes is mixed. The

ISCVT study noted a disparity in outcomes by sex, explained by the presence of sex-specific risk factors such as pregnancy and oral contraceptives, while multiple other studies failed to show this disparity.^{3,7,36,37} In this study, no difference in 90-day outcome was observed by sex or by peripartum status, and the use of birth control was not associated with poor outcome at 90-day follow-up or mortality in the multivariable analyses. Thus, providers should not assume a better or worse prognosis following CVT provoked by sex-specific risk factors.

Mortality in the ACTION-CVT cohort was lower than in previous studies. Compared to ISCVT, baseline patient characteristics were similar, and the rate of poor neurological outcome was similar between the studies. However, death during follow-up was less frequent at a rate of 5.12 per 100 person-years in ACTION-CVT, compared to 5.38 per 100 person-years in ISCVT.⁵ This mortality reduction may be due to improvements in stroke care and CVT diagnosis since the publication of ISCVT.

The prognostic factors identified in this study stratify patients into risk groups for poor outcome. The presence of zero risk factors identifies 36.8% (239/649) of the cohort with a much lower risk of poor outcome compared with the overall cohort (2.9% vs. 15.6%; 7/239 vs. 101/649; OR, 0.19). Meanwhile, the presence of three or more risk factors identifies a small subset of the cohort with a much higher risk of poor outcome compared with the overall cohort (57.6% vs. 15.6%; 28/59 vs. 101/649; OR, 3.70).

Risk stratification using the prognostic scores generated here may identify a group of patients with higher severity of illness who may benefit from new therapies, such as endovascular clot retrieval, in future trials. The recent Thrombolysis or Anti-coagulation for Cerebral Venous Thrombosis (TO-ACT) trial was stopped early as it was unable to meet its primary endpoint, despite an absolute reduction in the proportion of patients with a poor outcome at follow-up.³⁸ However, future trials may show a benefit with endovascular therapy if conducted in patients at the highest risk of poor outcome.

While this work represents the largest study of patients with CVT to date, it is limited due to its observational, retrospective design. Bias may exist in this data due to the lack of standardized treatment protocol and observed differences may be due to a treatment effect rather than the variable under study. All-cause mortality was used in this study and deaths observed may not have been due to CVT directly, especially in patients with comorbidities such as active cancer. However, in comparison to disease-specific mortality, all-cause mortality is not susceptible to misclassification bias. Standardized training for the assessment of mRS was not provided to participating centers. Although the mRS scores were generated by either the treating

clinician or experienced researchers and stroke coordinators, previous research has noted only moderate inter-rater reliability of mRS scores, potentially decreasing statistical power.³⁹ Patients lost to follow-up prior to 90-day were a substantial minority of the study population. Based upon available data, those lost to follow-up likely had a similar clinical course as those with follow-up. The higher rate of substance use and higher median NIHSS would contribute a bias towards the null for an effect of these variables on both poor outcome and mortality. This study was conducted prior to the introduction of COVID-19 vaccinations, as a result, CVT cases caused by vaccine induced thrombotic thrombocytopenia were not captured. Although internal validation of models was conducted using the bootstrap method, the prognostic model of this study should be interpreted with caution. External validation of the IN-REvASC model is important for future study. It is unknown whether this score is generalizable to populations with substantially different patient characteristics or healthcare settings. Finally, the primary outcome of this study, mRS 3–6 at 90-day follow-up, was low at 15.6%. While this is consistent with prior studies,^{5,40} it is possible that other factors such as concomitant COVID-19 infection^{41,42} are relevant in the prognostication of CVT but were undetected in this study due to a small effect size.

Conclusions

Active cancer, age, Black race, encephalopathy or coma on presentation, decreased hemoglobin, higher NIHSS on presentation, and substance use were associated with poor outcome at 90-day follow-up following CVT. Active cancer, Black race, and substance use were also associated with mortality. The racial disparity in CVT outcomes, while in alignment with other types of stroke, requires further study. In contrast to previous literature, sex, clot location, and birth control use were not associated with any primary or secondary outcome in this study. These factors may not confer as high prognostic value to CVT as previously thought. The derived IN-REvASC model offers increased prognostic accuracy for the prediction of poor outcome at 90-day follow-up and mortality, compared to ISCVT-RS. IN-REvASC score cutoffs stratified patients into groups with significantly different outcomes at 90-day follow-up. Improved prognostication may aid in clinical decision making and allow for identification of patients with the possibility of benefit in future clinical trials.

Supplementary materials

Supplementary materials related to this article can be found online at <https://doi.org/10.5853/jos.2022.01606>.

Disclosure

Thanh Nguyen reports research support from Medtronic and the Society of Vascular and Interventional Neurology. Maurizio Paciaroni reports speaker honoraria from Sanofi-Aventis; Boehringer-Ingelheim, Bayer, BMS, Daiichi-Sankyo, Pfizer. Diana Aguiar de Sousa reports speaker fees from Bayer, travel support from Boehringer Ingelheim, participating in an advisory board for AstraZeneca, and DSMB participation for the SECRET trial, outside the submitted work.

Acknowledgments

This work has been partially supported by the Italian Ministry of Health Ricerca Corrente-IRCCS Multimedica. The complete list of members and affiliations can be found in Appendix 1.

References

1. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. *Stroke* 2016;47: 2180-2182.
2. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. *Stroke* 2012;43:3375-3377.
3. Salottolo K, Wagner J, Frei DF, Loy D, Bellon RJ, McCarthy K, et al. Epidemiology, endovascular treatment, and prognosis of cerebral venous thrombosis: US center study of 152 patients. *J Am Heart Assoc* 2017;6:e005480.
4. Ropper AH, Klein JP. Cerebral venous thrombosis. *N Engl J Med* 2021;385:59-64.
5. Ferro JM, Canhão P, Stam J, Boussier MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke* 2004;35:664-670.
6. Borhani Haghighi A, Edgell RC, Cruz-Flores S, Feen E, Piri-yawat P, Vora N, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. *Stroke* 2012;43:262-264.
7. Korathanakun P, Sathirapanya P, Geater SL, Petpichetchian W. Predictors of hospital outcome in patients with cerebral

- venous thrombosis. *J Stroke Cerebrovasc Dis* 2014;23:2725-2729.
8. Duman T, Uluduz D, Midi I, Bektas H, Kablan Y, Goksel BK, et al. A multicenter study of 1144 patients with cerebral venous thrombosis: the VENOST Study. *J Stroke Cerebrovasc Dis* 2017;26:1848-1857.
 9. Wasay M, Kaul S, Menon B, Dai AI, Saadatnia M, Malik A, et al. Asian study of cerebral venous thrombosis. *J Stroke Cerebrovasc Dis* 2019;28:104247.
 10. Ferro JM, Bacelar-Nicolau H, Rodrigues T, Bacelar-Nicolau L, Canhão P, Crassard I, et al. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. *Cerebrovasc Dis* 2009;28:39-44.
 11. Barboza MA, Chiquete E, Arauz A, Merlos-Benitez M, Quiroz-Compeán A, Barinagarrementeria F, et al. A practical score for prediction of outcome after cerebral venous thrombosis. *Front Neurol* 2018;9:882.
 12. Pongvarin N, Prayoonwiwat N, Ratanakorn D, Towanabut S, Tantirittisak T, Suwanwela N, et al. Thai venous stroke prognostic score: TV-SPSS. *J Med Assoc Thai* 2009;92:1413-1422.
 13. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Development and validation of a predictive outcome score of cerebral venous thrombosis. *J Neurol Sci* 2009;276:66-68.
 14. Barinagarrementeria F, Cantu C, Arredondo H. Aseptic cerebral venous thrombosis: proposed prognostic scale. *J Stroke Cerebrovasc Dis* 1992;2:34-39.
 15. Eskey CJ, Meyers PM, Nguyen TN, Ansari SA, Jayaraman M, McDougall CG, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association. *Circulation* 2018;137:e661-e689.
 16. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. *JAMA Neurol* 2019;76:1457-1465.
 17. Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, et al. Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study. *Stroke* 2022;53:728-738.
 18. Alimohammadi A, Kim DJ, Field TS. Updates in cerebral venous thrombosis. *Curr Cardiol Rep* 2022;24:43-50.
 19. Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, Henninger N, et al. Predictors of recurrent venous thrombosis after cerebral venous thrombosis: analysis of the ACTION-CVT Study. *Neurology* 2022 Forthcoming.
 20. Siegler JE, Shu L, Yaghi S, Salehi Omran S, Elnazeir M, Bakradze E, et al. Endovascular therapy for cerebral vein thrombosis: a propensity-matched analysis of anticoagulation in the treatment of cerebral venous thrombosis. *Neurosurgery* 2022 Aug 23 [Epub]. <https://doi.org/10.1227/neu.000000000002098>.
 21. Liberman AL, Kamel H, Mullen MT, Messé SR. International Classification of Diseases, ninth revision (ICD-9) diagnosis codes can identify cerebral venous thrombosis in hospitalized adults. *Neurohospitalist* 2016;6:147-150.
 22. Handley JD, Emsley HC. Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. *Health Inf Manag* 2020;49:58-61.
 23. Burke JF, Freedman VA, Lisabeth LD, Brown DL, Haggins A, Skolarus LE. Racial differences in disability after stroke: results from a nationwide study. *Neurology* 2014;83:390-397.
 24. Clayton P. CUTPT: Stata module for empirical estimation of cutpoint for a diagnostic test. IDEAS. <https://ideas.repec.org/c/boc/bocode/s457719.html>. 2013. Accessed August 30, 2022.
 25. Canhão P, Ferro JM, Lindgren AG, Boussier MG, Stam J, Barinagarrementeria F, et al. Causes and predictors of death in cerebral venous thrombosis. *Stroke* 2005;36:1720-1725.
 26. Girot M, Ferro JM, Canhão P, Stam J, Boussier MG, Barinagarrementeria F, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. *Stroke* 2007;38:337-342.
 27. Otite FO, Patel S, Sharma R, Khandwala P, Desai D, Latorre JG, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. *Neurology* 2020;95:e2200-e2213.
 28. Williams O, Ovbiagele B. Stroking out while Black: the complex role of racism. *JAMA Neurol* 2020;77:1343-1344.
 29. Levine DA, Duncan PW, Nguyen-Huynh MN, Ogedegbe OG. Interventions targeting racial/ethnic disparities in stroke prevention and treatment. *Stroke* 2020;51:3425-3432.
 30. Churchwell K, Elkind MS, Benjamin RM, Carson AP, Chang EK, Lawrence W, et al. Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association. *Circulation* 2020;142:e454-e468.
 31. Skolarus LE, Sharrief A, Gardener H, Jenkins C, Boden-Albala B. Considerations in addressing social determinants of health to reduce racial/ethnic disparities in stroke outcomes in the United States. *Stroke* 2020;51:3433-3439.
 32. Magwood GS, Ellis C, Nichols M, Burns SP, Jenkins C, Woodbury M, et al. Barriers and facilitators of stroke recovery: perspectives from African Americans with stroke, caregivers and healthcare professionals. *J Stroke Cerebrovasc Dis* 2019;

- 28:2506–2516.
33. Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, et al. Impact of hemoglobin levels and anemia on mortality in acute stroke: analysis of UK regional registry data, systematic review, and meta-analysis. *J Am Heart Assoc* 2016;5:e003019.
 34. Silvis SM, Reinstra E, Hiltunen S, Lindgren E, Heldner MR, Mansour M, et al. Anaemia at admission is associated with poor clinical outcome in cerebral venous thrombosis. *Eur J Neurol* 2020;27:716–722.
 35. Liu K, Pei L, Gao Y, Zhao L, Fang H, Bunda B, et al. Dehydration status predicts short-term and long-term outcomes in patients with cerebral venous thrombosis. *Neurocrit Care* 2019;30:478–483.
 36. Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Cantú C, Bousser MG, et al. Cerebral venous and sinus thrombosis in women. *Stroke* 2009;40:2356–2361.
 37. Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ, Torres-Anguiano C, González-Padilla C, Arauz A, et al. Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: the RENAMEVASC study. *J Stroke Cerebrovasc Dis* 2012;21:395–400.
 38. Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhão P, Roos YB, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT Randomized Clinical Trial. *JAMA Neurol* 2020;77:966–973.
 39. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a systematic review. *Stroke* 2009;40:3393–3395.
 40. Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. *J Thromb Haemost* 2012;10:1297–1302.
 41. Nguyen TN, Qureshi MM, Klein P, Yamagami H, Abdalkader M, Mikulik R, et al. Global impact of the COVID-19 pandemic on cerebral venous thrombosis and mortality. *J Stroke* 2022;24:256–265.
 42. Siegler JE, Abdalkader M, Michel P, Nguyen TN. Therapeutic trends of cerebrovascular disease during the COVID-19 pandemic and future perspectives. *J Stroke* 2022;24:179–188.

Appendix 1. The ACTION-CVT study group

Author	Affiliation
Ekaterina Bakradze	Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA
James A. Giles	Department of Neurology, Washington University, Saint Louis, MO, USA
Jordan Y. Amar	Department of Neurology, Washington University, Saint Louis, MO, USA
Nils Henninger	Department of Neurology, University of Massachusetts, Worcester, MA, USA; Department of Psychiatry, University of Massachusetts, Worcester, MA, USA
Marwa Elnazeir	Department of Neurology, University of Massachusetts, Worcester, MA, USA
Ava L. Liberman	Department of Neurology, Weill Cornell Medical Center, New York, NY, USA
Khadean Moncrieffe	Department of Neurology, Montefiore Medical Center, New York, NY, USA
Jenny Lu	Department of Neurology, Montefiore Medical Center, New York, NY, USA
Richa Sharma	Department of Neurology, Yale University, New Haven, CT, USA
Yee Cheng	Department of Neurology, Yale University, New Haven, CT, USA
Adeel S. Zubair	Department of Neurology, Yale University, New Haven, CT, USA
Grace T. Li	Department of Neurology, University of Florida, Gainesville, FL, USA
Justin Chi Kung	Department of Neurology, University of Florida, Gainesville, FL, USA
Dezaray Perez	Department of Neurology, University of Florida, Gainesville, FL, USA
Adrian Scutelnic	Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland
David Seiffge	Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland
Bernhard Siepen	Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland
Aaron Rothstein	Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Ossama Khazaal	Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
David Do	Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Sami Al Kasab	Department of Neurology, Medical University of South Carolina, Charleston, SC, USA; Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA
Line Abdul Rahman	Department of Neurology, Medical University of South Carolina, Charleston, SC, USA
Eva A. Mistry	Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Deborah Kerrigan	Department of Neurology, Vanderbilt University, Nashville, TN, USA
Hayden Lafever	Department of Neurology, Vanderbilt University, Nashville, TN, USA
Jennifer Frontera	Department of Neurology, New York University, New York, NY, USA
Lindsey Kuohn	Department of Neurology, New York University, New York, NY, USA
Shashank Agarwal	Department of Neurology, New York University, New York, NY, USA
Christoph Stretz	Department of Neurology, Brown University, Providence, RI, USA
Narendra Kala	Department of Neurology, Brown University, Providence, RI, USA
Sleiman El Jamal	Department of Neurology, Brown University, Providence, RI, USA
Alison Chang	Department of Neurology, Brown University, Providence, RI, USA
Shawna Cutting	Department of Neurology, Brown University, Providence, RI, USA
Han Xiao	Department of Biostatistics, University of California Santa Barbara, Santa Barbara, CA, USA
Varsha Muddasani	Department of Neurology, University of Utah, Salt Lake City, UT, USA
Teddy Wu	Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
Duncan Wilson	Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
Amre Nouh	Department of Neurology, Hartford Hospital, Hartford, CT, USA
Syed Daniyal Assad	Department of Neurology, Hartford Hospital, Hartford, CT, USA
Abid Qureshi	Department of Neurology, University of Kansas, Kansas City, KS, USA
Justin Moore	Department of Neurology, University of Kansas, Kansas City, KS, USA
Pooja Khatri	Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Yasmin Aziz	Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Bryce Casteigne	Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Appendix 1. Continued

Author	Affiliation
Muhib Khan	Department of Neurology, Spectrum Health, Michigan State University, Grand Rapids, MI, USA
Yao Cheng	Department of Neurology, Spectrum Health, Michigan State University, Grand Rapids, MI, USA
Brian Mac Grory	Department of Neurology, Duke University, Durham, NC, USA
Martin Weiss	Department of Neurology, Duke University, Durham, NC, USA
Dylan Ryan	Department of Neurology, Duke University, Durham, NC, USA
Scott Kamen	Department of Neurology, Cooper University, Camden, NJ, USA
Siyuan Yu	Department of Neurology, Cooper University, Camden, NJ, USA
Christopher R. Leon Guerrero	Department of Neurology, George Washington University, District of Columbia, USA
Eugenie Atallah	Department of Neurology, George Washington University, District of Columbia, USA
Gian Marco De Marchis	Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland
Alex Brehm	Department of Interventional and Diagnostic Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Basel, Switzerland
Tolga Ditrach	Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland
Ronald Alvarado-Dyer	Department of Neurology, University of Chicago, Chicago, IL, USA
Tareq Kass-Hout	Department of Neurology, University of Chicago, Chicago, IL, USA
Shyam Prabhakaran	Department of Neurology, University of Chicago, Chicago, IL, USA
Tristan Honda	Department of Neurology, University of California at Los Angeles, Los Angeles, CA, USA
Karen Furie	Department of Neurology, Brown University, Providence, RI, USA

Supplementary Table 1. TRIPOD reporting guidelines checklist

Section/topic	Item	Checklist item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	4
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	4
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	5
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	5
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	5-6
	5b	Describe eligibility criteria for participants.	5-6
	5c	Give details of treatments received, if relevant.	n/a
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	6-7
	6b	Report any actions to blind assessment of the outcome to be predicted.	6-7
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	6
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	6
Sample size	8	Explain how the study size was arrived at.	5
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	5-6
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.	6-7
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	7-8
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	7-8
Risk groups	11	Provide details on how risk groups were created, if done.	7
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	8, Fig 1
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	8-10
Model development	14a	Specify the number of participants and outcome events in each analysis.	8-10
	14b	If done, report the unadjusted association between each candidate predictor and outcome.	8-10, Table 2
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	9, Fig 2, Fig 3
	15b	Explain how to use the prediction model.	9
Model performance	16	Report performance measures (with confidence intervals) for the prediction model.	9, Fig 2
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	13-14
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	10-11
Implications	20	Discuss the potential clinical use of the model and implications for future research.	10-11, 14-15
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	5
Funding	22	Give the source of funding and the role of the funders for the present study.	15